Pharmstandard To Spin Off OTC Business, Acquire Bever Pharma
This article was originally published in PharmAsia News
Executive Summary
Russia's Pharmstandard plans to buy Singapore's Bever Pharmaceutical for $630 million, raising the funds by spinning off its over-the-counter branded drugs business.